PVLA · Palvella Therapeutics, Inc.

Palvella Therapeutics reported its first quarter 2026 financial results, reflecting a net loss of $15.8 million ($1.20 per share) compared to a net loss of $8.2 million ($0.74 per share) in the same period last year. The increased loss was driven by higher research and development expenses of $9.3 million (up from $4.1 million) due to manufacturing activities, headcount growth, and consulting services, as well as higher general and administrative expenses of $5.5 million (up from $3.8 million) from increased headcount and professional services related to being a public company. The company ended the quarter with $261.9 million in cash, cash equivalents, and short-term investments, bolstered by a $230 million upsized equity financing in February 2026. Operationally, Palvella is advancing its lead candidate QTORIN rapamycin for microcystic lymphatic malformations (LMs) toward an NDA submission in the second half of 2026, following positive Phase 3 SELVA results. The FDA has granted a pre-NDA meeting expected in Q2 2026. The company is also preparing for a potential U.S. commercial launch in the first half of 2027, having recruited experienced commercial leadership. Pipeline expansion includes planned Phase 3 initiation for cutaneous venous malformations in H2 2026, Phase 2 LOTU trial for angiokeratomas (first patients dosed), and Phase 2 trial for DSAP in H2 2026. The company also plans to announce a third QTORIN product candidate and a fourth indication for QTORIN rapamycin in H2 2026. Management commentary emphasized a clear path to near-term NDA submission and the strength of the balance sheet to support commercialization.